While interest in immuno-oncology runs deep across the industry, a handful of companies are leading the pack. Scrip offers a side-by-side look at the IO portfolios for BMS, Merck, Roche and AstraZeneca.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.
Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.
